premenstrual%20dysphoric%20disorder
PREMENSTRUAL DYSPHORIC DISORDER
Premenstrual dysphoric disorder is a cyclical disorder presenting with distressing mood and behavioral symptoms that occur during the late luteal phase of the ovulatory cycle; it is a severe form of premenstrual syndrome.
It results in considerable impairment of the patient's personal functioning that occurs in approximately 5% of women of reproductive age.

Premenstrual%20dysphoric%20disorder Signs and Symptoms

Introduction

Premenstrual Syndrome (PMS)

  • PMS is a group of recurrent mild to moderate physical and/or emotional symptoms occurring during the late luteal phase of the ovulatory cycle that do not usually interfere with the patient’s usual level of function
    • Occurs in approximately 75% of women of reproductive age, among whom 20-50% report moderate to severe symptoms

Definition

Premenstrual Dysphoric Disorder (PMDD)

  • PMDD is a cyclical disorder presenting with distressing mood and behavioral symptoms that occur during the late luteal phase of the ovulatory cycle; it is a severe form of PMS
  • PMDD results in considerable impairment of the patient’s personal functioning
    • Occurs in approximately 5% of women of reproductive age

Underlying Medical and Psychiatric Disorders

The following medical conditions may mimic PMDD with premenstrual exacerbation:
  • Allergies
  • Anemia
  • Asthma
  • Autoimmune or collagen vascular disorders
  • Chronic fatigue syndrome
  • Endometriosis
  • Endocrine disorders [diabetes mellitus (DM), hypothyroidism]
  • Epilepsy
  • Hyperprolactinemia
  • Irritable bowel syndrome
  • Migraine
  • Panhypopituitarism
  • Polycystic ovarian disease

The following psychiatric conditions may mimic PMDD with premenstrual exacerbation:

  • Anxiety disorders
  • Bipolar disorder
  • Bulimia
  • Cyclothymic disorder
  • Depression
  • Dysthymic disorder
  • Posttraumatic stress disorder
  • Psychosocial (current victim of physical abuse or history of sexual abuse)
  • Panic disorder
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.